Squarepoint’s Tempest Therapeutics TPST Stock Holding History

Squarepoint’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.3K	Buy	+30,900	New	+$51K	﹤0.01%	4288
2021 Q2	–	Sell	-435	Closed	-$102K	–	3693
2021 Q1	$102K	Buy	+435	New	+$176K	﹤0.01%	2902
2020 Q2	–	Sell	-135	Closed	-$139K	–	2516
2020 Q1	$139K	Sell	135 -32	-19%	-$46.7K	﹤0.01%	1578
2019 Q4	$220K	Buy	167 +73	+78%	+$103K	﹤0.01%	2192
2019 Q3	$130K	Buy	94 +41	+77%	+$66.2K	﹤0.01%	2156
2019 Q2	$119K	Buy	+53	New	+$156K	﹤0.01%	2202
2018 Q1	–	Sell	-30	Closed	-$122K	–	2147
2017 Q4	$122K	Buy	+30	New	+$126K	﹤0.01%	1919
2017 Q1	–	Sell	-7	Closed	-$30K	–	1911
2016 Q4	$30K	Buy	+7	New	+$87.2K	﹤0.01%	1720
2016 Q1	–	Sell	-5	Closed	-$142K	–	1449
2015 Q4	$142K	Buy	+5	New	+$165K	0.02%	1080

Other funds holding TPST

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Squarepoint's TPST Position: Q2 2026 in Review

Squarepoint opened a new position in Tempest Therapeutics (TPST) in Q2 2026: 30,900 shares worth $34.3K. The stake represents ﹤0.01% of the portfolio and ranks #4288 among its holdings. This is a return to the name: Squarepoint previously reported a position in TPST as recently as Q1 2021.

Squarepoint first reported a position in TPST in Q4 2015 and has held it in 9 quarters since. The position peaked at $220K in Q4 2019. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.

Squarepoint held 30,900 shares of Tempest Therapeutics worth $34.3K as of Q2 2026.
Tempest Therapeutics was a new Squarepoint position in Q2 2026.
Tempest Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4288 holding.
Squarepoint first reported a position in Tempest Therapeutics in Q4 2015 and has held it in 9 quarters since.
Squarepoint's Tempest Therapeutics position peaked at $220K in Q4 2019.
21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.